Skip to main content
LIFECORE BIOMEDICAL, INC. \DE\ logo

LIFECORE BIOMEDICAL, INC. \DE\ — Investor Relations & Filings

Ticker · LFCR ISIN · US5147661046 LEI · 549300EHBZ5OM9ND9O43 US Manufacturing
Filings indexed 1,096 across all filing types
Latest filing 2017-05-26 Director's Dealing
Country US United States of America
Listing US LFCR

About LIFECORE BIOMEDICAL, INC. \DE\

https://www.lifecore.com/

Lifecore Biomedical is an integrated contract development and manufacturing organization (CDMO) that specializes in sterile injectable pharmaceutical drug products and medical devices. The company provides a full range of services, including specialty formulation, process development, aseptic filling, and final packaging, supporting products from clinical phases through to commercial supply. A key area of expertise is the handling of complex and highly viscous formulations. In addition to its CDMO capabilities, Lifecore is a primary producer of non-animal-sourced sodium hyaluronate (hyaluronic acid), offering it in various molecular weights and formats, including bulk material, hydrogels, and filled syringes and vials for diverse applications.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2017-05-26 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details changes in compensation structure and salary adjustments for executives, which falls under announcements related to management changes or arrangements. The key section is Item 5.02, which concerns departure, election, or appointment of directors or officers and compensatory arrangements. This matches the category for Board/Management Information (MANG). The document length is 4113 characters, which is short but contains substantive information about management compensation changes, not just an announcement of a report. Therefore, it is not a report publication announcement or regulatory filing fallback. Hence, the classification is MANG with high confidence.
2017-05-26 English
FORM 4
Director's Dealing
2017-05-24 English
FORM 4
Director's Dealing
2017-05-24 English
FORM 4
Director's Dealing
2017-05-19 English
FORM 4
Director's Dealing
2017-05-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.